Arkolith/Insider Trading/URGN/Form 4

Schoenberg Mark

Chief Medical OfficerUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Jun 9, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$143K
Net Open-Market Flow
-$143K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 8, 2026Option exercise(M)10K——145K
Jun 8, 2026Sell(S)5K$27.30$143K140K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 8, 2026Option exercise(M)10K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-019964) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML